Peter Starke

Peter Starke
U.S. Food and Drug Administration | FDA · Center for Drug Evaluation and Research

About

6
Publications
3,211
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
547
Citations

Publications

Publications (6)
Article
Full-text available
In 1994, the US Food and Drug Administration (FDA) proposed an approach, based on extrapolation of efficacy findings from adults to the pediatric population, to maximize the use of adult data and other data when designing pediatric drug-development programs. We examined the experience of the FDA in using extrapolation to evaluate how and when it wa...
Article
Risk of anaphylaxis is included in the prescribing information for omalizumab, but the nature of these reactions merits further elaboration. To describe cases of anaphylaxis associated with omalizumab administration in patients with asthma. We reviewed spontaneous postmarketing adverse event reports submitted to the US Food and Drug Administration'...
Article
Full-text available
To the Editor: In late 2004, a “boxed warning” was added to the labeling for promethazine hydrochloride (Phenergan), including a contraindication for use in children less than two years of age and a strengthened warning with regard to use in children two years of age or older. We describe the basis for this action. Promethazine is widely used in ch...
Article
To the Editor: Dr Dolor and colleagues¹ concluded that intranasal corticosteroids are efficacious in the treatment of acute rhinosinusitis. We believe, however, that the design of their trial significantly limits the conclusions that can be drawn from it. We believe the trial design was more like that of a large simple trial rather than a well-cont...

Network

Cited By